In their study, they conducted in vitro experiments by targeting G47Δ (third-generation tumour lysing recombinant HSV-1) and Lp2-CAR-T cells to glioblastomas cells, and found the combination of the two treatments further reduced the viability of the cancer cells and inhibited their growth even more significantly; the in vivo experiments not only inhibited tumour growth but also prolonged the survival of mice. The gene discussed is RPLP2; the disease is neoplasm.